what type of glp 1 is mounjaro Who A Candidate For Or GLP-1 Treatment What Makes Mounjaro Different From

PMID 25038357

Phase 2 trial data (published in New England Journal of Medicine, 2023 ): 24.2% average weight loss at 48 weeks with 12 mg dose 22.8% with 8 mg dose Placebo group lost 2.1% Most recent Phase 3 trial data (TRIUMPH-4, December 2025): 28.7% average weight loss at 68 weeks with 12 mg dose 26.4% with 9 mg dose 58.6% of participants on 12 mg achieved at least 25% weight loss 39.4% achieved at least 30% weight loss For context: These are the highest weight loss numbers reported in any clinical trial for a pharmacological obesity treatment

Canceling early can make a patient ineligible

In Phase 2 clinical trials, the safety profile was broadly consistent with other incretin-based therapies, with gastrointestinal side effects being the most commonly reported

Book a free consultation, including a free Body Composition Scan, to see if you qualify and find a dose that works for you